Enveric Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
ENVB$1.51+4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(17,291,732) | $(18,471,333) |
| Adjustments to reconcile net loss to cash used in operating activities | ||
| Change in fair value of warrant liability | (94,396) | (4,315,236) |
| Change in fair value of investment option liability | (208,752) | (3,472,726) |
| Change in fair value of derivative liability | (727,000) | 325,000 |
| Stock-based compensation | 2,150,160 | 2,620,671 |
| Inducement expense | 1,848,235 | — |
| Impairment of intangibles | — | 7,453,662 |
| Non-cash income tax benefit | — | (1,504,302) |
| Amortization of ROU asset | 64,048 | 107,291 |
| Amortization of intangibles | 168,754 | 168,750 |
| Depreciation expense | 175,228 | 159,160 |
| Gain on disposal of property and equipment | (4,206) | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (6,857) | (374,058) |
| Accounts payable and accrued liabilities | (103,848) | 263,686 |
| Right-of-use operating lease asset and obligation | (64,045) | (107,288) |
| Net cash used in operating activities | (14,094,411) | (17,146,723) |
| Cash Flows From Investing Activities: | ||
| Purchases of property and equipment | (5,180) | (584,165) |
| Proceeds from disposal of property and equipment | 16,847 | — |
| Net cash provided by (used in) investing activities | 11,667 | (584,165) |
| Cash Flows From Financing Activities: | ||
| Proceeds from sale of common stock, warrants, and investment options, net of offering costs | — | 17,222,099 |
| Payment for equity distribution offering costs | (291,084) | — |
| Redemption of Series A Preferred Stock | (1,052,057) | — |
| Proceeds from the sale of redeemable non-controlling interest, net of offering costs | — | 958,038 |
| Net cash (used in) provided by financing activities | (1,343,141) | 18,180,137 |
| Effect of Foreign Exchange Rate on Changes on Cash | (10,022) | (81,364) |
| Net (decrease) increase in cash | (15,435,907) | 367,885 |
| Cash at beginning of year | 17,723,884 | 17,355,999 |
| Cash at end of year | $2,287,977 | $17,723,884 |
| Supplemental disclosure of cash and non-cash transactions: | ||
| Cash paid for interest | $— | $5,249 |
| Income taxes paid | $9,507 | $— |
| Warrants issued in conjunction with common stock issuance | $— | $3,595,420 |
| Issuance of embedded derivative | $— | $402,000 |
|---|---|---|
| Stock subscription receivable | $1,817,640 | $— |
| Offering costs accrued not paid | $182,724 | $— |
| Warrants issued for offering costs | $77,991 | $— |
| Issuance of common shares for deferred offering costs | $255,107 | $— |
| Induced conversion of warrants and preferred investment options | $683,997 | $— |
| Preferred dividends attributable to redeemable non-controlling interest | $19,041 | $33,014 |
| Investment options issued in conjunction with common stock issuance | $— | $4,323,734 |
| Modification of warrants as part of share capital raise | $— | $251,357 |
| Accretion of embedded derivative to redemption value | $147,988 | $295,976 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.